Association Between Clinical Progression in Multiple System Atrophy and Brain Volume Changes Evaluated via Deep Learning Segmentation
Objective: Assess brain volume changes in patients with multiple system atrophy (MSA) over one year. Background: Identifying disease progression biomarkers is crucial for advancing MSA…Safety and Efficacy of the Anti-alpha Synuclein Monoclonal Antibody Lu AF82422 for the Treatment of Patients with MSA: Results from the Phase 2 AMULET Trial
Objective: Assess the efficacy and safety of monthly IV infusions with the anti-alpha synuclein [a-syn] monoclonal antibody Lu AF82422 for the treatment of patients with…Exploring Vestibulopathy in PD: Distinguishing PD from Age-related Presbyvestibulopathy via Dynamic Gait and Balance Assessment
Objective: To investigate the influence of age-associated vestibulopathy (presbyvestibulopathy, PVP) on dynamic gait and balance in Parkinson's disease (PD) patients and elderly controls. We hypothesized…Early Dementia with Lewy Bodies and Parkinson’s Disease with RBD: two faces of the same coin?
Objective: To describe clinical and imaging differences in de novo PD with and without REM sleep Behaviour Disorder (dnPDRBD – de novo PD) and de…α-Synuclein Pathology Across Movement Disorders and Neurodegenerative Diseases by Seed Amplification Assay
Objective: To assess the frequency of pathological α-synuclein (αSyn) in various movement disorders and neurodegenerative diseases from a specialized movement disorder clinic by αSyn seed…A Phase 2 Study of ATH434 a Novel Inhibitor of α-Synuclein Aggregation for the Treatment of Multiple System Atrophy
Objective: Describe baseline fluid and neuroimaging biomarker data of an early MSA study population Background: MSA is a rapidly progressive neurodegenerative disorder characterized by aggregated…Accuracy of Clinical features for Substantia Nigra Hypopigmentation and Cortical Lewy Body Presence in the Oldest-Old: The 90+ Study
Objective: To improve clinical diagnostic accuracy of Lewy Body Dementia (LBD), we assessed if frontal release signs are a useful screening tool for cortical Lewy…New α-Synuclein Strain Biomarker in Parkinson’s Disease and Related Dementia
Objective: Biomarker development for Parkinson’s disease and related dementia. Background: α-Synuclein (α-syn) strains can serve as discriminators of Parkinson's disease (PD) from other α-synucleinopathies. However,…Association Between DPP-4 Inhibitors Use and Risk of Dementia: A Meta-analysis Using Real-world Data
Objective: To investigate the potential association between the use of DPP-4 inhibitors and the risk of dementia, utilizing real-world data from diverse sources. Background: Evidence…Progression of motor asymmetry in the MDS-UPDRS III in Parkinson’s Disease with and without REM Sleep Behavior Disorder over five years
Objective: To compare progression of motor asymmetry using the MDS-UPDRS-III in Parkinson’s Disease (PD) with and without probable REM Sleep Behavior disorder (pRBD) over 5…
- « Previous Page
- 1
- …
- 80
- 81
- 82
- 83
- 84
- …
- 1554
- Next Page »